
1. vox sang. 2019 jul;114(5):467-477. doi: 10.1111/vox.12788. epub 2019 may 26.

health economic implications testing blood donors south africa htlv 1 &
2 infection.

vermeulen m(1), van den berg k(1), sykes w(1), reddy r(1), ingram c(2), poole
c(1), custer b(3)(4).

author information: 
(1)south african national blood service, weltevreden park, south africa.
(2)south african bone marrow registry, cape town, south africa.
(3)vitalant research institute, san francisco, ca, usa.
(4)department laboratory medicine, university california san francisco, san
francisco, ca, usa.

background objectives: currently, htlv screening performed south
africa (sa). report describes economic assessment (budget impact and
cost-effectiveness) implementing different htlv screening strategies.
methods: modified version alliance blood operators risk-based
decision-making framework used assess risk consequences htlv in
the blood supply sa. developed deterministic model cost and
consequences four screening strategies: none, universal, donors and
first time donors assuming transfusion-transmission (tt) efficiency 10%
and manifestation clinical disease 6%.
results: unscreened blood results 3·55 symptomatic tt-htlv cases total
healthcare cost rand (r)3 446 950 (us dollars (usd)229 800) annually.
universal screening would cost r24 000 000 (usd1 600 000) per annum prevent
3·54 (99·8%) symptomatic tt-htlv cases first year 0·55 (98·4%)
symptomatic tt-htlv cases second year cost per tt-htlv prevented of
r6 780 000 (usd450 000) year one r43 254 000 (usd2 890 000) year two.
screening donors would cost r16,200,000 (usd1 080 000) r4 600 000
(usd306 000) per symptomatic tt-htlv infection prevented year one. total costs
decrease r5 100 000 (usd340 000) year 2 cost per tt-htlv prevented 
increases r10 700 000 (usd713 333).
conclusion: analysis contributed decision implement htlv
screening healthcare budget particularly budget blood
transfusion sa insufficient provide appropriate treatment. arguably,
available resources efficiently utilized healthcare
programs.

© 2019 international society blood transfusion.

doi: 10.1111/vox.12788 
pmcid: pmc7370940
pmid: 31131453  [indexed medline]

